April 23, 2014 / 11:26 AM / 3 years ago

Spectrum Pharma's cancer drug meets main goal in trial

April 23 (Reuters) - Spectrum Pharmaceuticals said its experimental cancer drug was shown to be safe and effective in a mid-stage trial.

Spectrum’s drug, Captisol-enabled melphalan, is an intravenous formulation of a common chemotherapy drug melphalan, and is being tested in multiple myeloma patients undergoing stem cell transplants.

The company said it expects to file for a regulatory approval in the third quarter.

Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below